Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
Altos Labs
Biotech
Bob Nelsen on megarounds, Altos and psychedelics
Arch's Bob Nelsen says if Xaira Therapeutics can realize its potential, then the $1 billion initial financing will likely be just the beginning.
Max Bayer
May 1, 2024 10:56am
Biotech's top money raisers: 2022
Apr 11, 2023 9:19am
Despite blockbuster Altos funds, longevity investment falls $1B
Jan 31, 2023 11:28am
Agios replaces CEO after recent FDA nod—Chutes & Ladders
Jul 15, 2022 9:30am
Biotech's top 10 money raisers of 2021
Apr 18, 2022 3:00am
GSK to Bezos-backed biotech: Barron hops jobs—Chutes & Ladders
Jan 21, 2022 9:30am
